Google- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for ... - RTT News (press release)
| <img alt="" height="1" width="1" />Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for ...RTT News (press release)N=435) in patients with Irritable Bowel Syndrome with Constipation, the most common adverse reactions (incidence >4%) were nausea (8% vs. ...<nobr>and more »</nobr> |
1 - 1 of 1 Posts
1 - 1 of 1 Posts
- This is an older thread, you may not receive a response, and could be reviving an old thread. Please consider creating a new thread.
Irritable Bowel Syndrome and Digestive Health Support Forum
A forum community dedicated to Irritable Bowel Syndrome and Digestive Health Support. Come join the discussion about treatment, diet, health, lifestyles, spirituality, medication, research, recovery, and more!
Full Forum Listing
